Feature|Videos|May 28, 2024
A Different CDMO Experience: Q&A With Scorpius’ President & COO Joe Payne
Author(s)Scorpius BioManufacturing
Joe Payne, Scorpius BioManufacturing, comments on the unique needs of today's biopharmaceutical companies looking to develop and manufacture small-volume, early-stage large molecules.
Watch the video and learn more:
- Learn about Scorpius’ president and COO, Joe Payne, as a thought leader who is also approachable, energetic, and in-tune with client needs.
- Learn about Scorpius’ competitive advantages in biomanufacturing of small-volume, early-stage large molecules.
- Learn what it takes to produce an end product that can be shared with both prospective clients and prospective employees.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First
2
PharmTech Weekly News Roundup – Week of December 1, 2025
3
Immortal Dragons Will Help Etheros Target Aging and Related Diseases
4
BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation
5
